Why Glycomimetics Is Ripping 19% Higher Today

After reporting on Wednesday that a mid-stage drug in clinical trials has received FDA breakthrough designation and releasing additional data from its trial on Thursday, shares of GlycoMimetics (NASDAQ: GLYC) have more than doubled, including a 19% rally on Friday as of 1 p.m EDT.GlycoMimetics is developing GMI-1271 for use in adults with relapsed or refractory acute myeloid leukemia (AML). Image source: Getty Images.Continue reading

Topics:  fda   glycomimetics nasdaq   glyc    edt    aml image   images   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News